Targeting P2Y13 Receptor: New Hope for Chronic Migraine Relief

Research Summary

New research published in the Journal of Headache and Pain highlights the role of the P2Y13 receptor in chronic migraine (CM). Utilizing a mouse model, scientists discovered that the P2Y13 receptor is highly active in microglia within the trigeminal nucleus caudalis (TNC) during CM. Inhibiting this receptor reduced hyperalgesia and central sensitization, as well as lowered levels of the pain-related molecules CGRP and c-Fos. Additionally, blocking the p38 MAPK signaling pathway, which is activated in the TNC during CM, also decreased microglial activation and inflammation. These findings suggest targeting P2Y13 could be a promising strategy for managing CM.

Study Details

📄 Title: The P2Y13 receptor-mediated microglial morphological transformation through the p38MAPK signaling pathway contributes to central sensitization in a murine model of chronic migraine.

👥 Research Team: Yang Y et al.

📚 Published In: J Headache Pain

📅 Publication Date: 2025 Dec 15

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.